BioNTech (Nasdaq: BNTX, “BioNTech”) and Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) today announced that they have entered into a definitive merger agreement under which BioNTech will acquire Neon in an all-stock transaction valued at approximately $67.0 million. Neon is a biotechnology company developing novel neoantigen-based T cell therapies. Upon closing, it will operate as a subsidiary of BioNTech, a global clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The transaction will combine two organizations with a common culture of pioneering translational science and a shared vision for the future of cancer immunotherapy.
Read the full article: BioNTech to Acquire Neon to Strengthen Global Leadership Position in T Cell Therapies //
Source: https://www.globenewswire.com/news-release/2020/01/16/1971361/0/en/BioNTech-to-acquire-Neon-to-strengthen-global-leadership-position-in-T-cell-therapies.html